{"protocolSection":{"identificationModule":{"nctId":"NCT02201121","orgStudyIdInfo":{"id":"plaghran001"},"organization":{"fullName":"Chinese PLA General Hospital","class":"OTHER"},"briefTitle":"Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation","officialTitle":"Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation"},"statusModule":{"statusVerifiedDate":"2013-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-03"},"primaryCompletionDateStruct":{"date":"2014-06","type":"ACTUAL"},"completionDateStruct":{"date":"2014-06","type":"ACTUAL"},"studyFirstSubmitDate":"2014-07-22","studyFirstSubmitQcDate":"2014-07-24","studyFirstPostDateStruct":{"date":"2014-07-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-07-24","lastUpdatePostDateStruct":{"date":"2014-07-25","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ran Kong","investigatorTitle":"Department of Anesthesiology, People's Liberation Army General Hospital, Beijing, China","investigatorAffiliation":"Chinese PLA General Hospital"},"leadSponsor":{"name":"Chinese PLA General Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Although induced hypertension decreased SVV and PPV,the influences of stroke volume variation and pulse pressure variation caused by phenylephrine,dopamine and ephedrine were unknown.","detailedDescription":"Pulse pressure variation (PPV) and stroke volume variation (SVV) during mechanical ventilation have been shown to be effective parameters to predict preload responsiveness. Although induced hypertension decreases PPV and SVV, the influences of phenylephrine, dopamine and ephedrine on PPV and SVV are unknown."},"conditionsModule":{"conditions":["Circulation","Drug Dose","Calculated SAP"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":94,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"phenylephrine group, dopamine group, ephedrine group","type":"EXPERIMENTAL","description":"phenylephrine group: use the phenylephrine to increase the SAP from low to high level.\n\ndopamine group: use the dopamine to increase the SAP from low to high level. ephedrine group:use the ephedrine to increase the SAP from low to high level.","interventionNames":["Other: Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation"]}],"interventions":[{"type":"OTHER","name":"Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation","description":"This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure","armGroupLabels":["phenylephrine group, dopamine group, ephedrine group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"invasive arterial blood pressure as a Measure of Safety","description":"if instability of circulation, stop the clinical trial","timeFrame":"DAY 1"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Their American Society of Anesthesiologists (ASA) physical status was 1 or 2\n* Body mass index (BMI) ranged from 18 to 26\n* None of the patients had known diabetes mellitus, hypertension, cardiovascular, pulmonary, endocrinological, neurological diseases, or diseases that influenced intravascular fluid volume or balance\n* All patients had a preoperative fast for at least 8 h and routine atropine intramuscular injection\n\nExclusion Criteria:\n\n* Persistent arrhythmias\n* Intraoperative application of vasoactive drugs except phenylephrine, dopamine and ephedrine","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010656","term":"Phenylephrine"},{"id":"D000004298","term":"Dopamine"},{"id":"D000010109","term":"Oxymetazoline"},{"id":"D000004809","term":"Ephedrine"}],"ancestors":[{"id":"D000002316","term":"Cardiotonic Agents"},{"id":"D000009184","term":"Mydriatics"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000013566","term":"Sympathomimetics"},{"id":"D000014662","term":"Vasoconstrictor Agents"},{"id":"D000014663","term":"Nasal Decongestants"},{"id":"D000019141","term":"Respiratory System Agents"},{"id":"D000058646","term":"Adrenergic alpha-1 Receptor Agonists"},{"id":"D000000316","term":"Adrenergic alpha-Agonists"},{"id":"D000000322","term":"Adrenergic Agonists"},{"id":"D000018663","term":"Adrenergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000000697","term":"Central Nervous System Stimulants"},{"id":"D000015259","term":"Dopamine Agents"}],"browseLeaves":[{"id":"M7656","name":"Ephedrine","asFound":"Psilocybin","relevance":"HIGH"},{"id":"M27276","name":"Pseudoephedrine","relevance":"LOW"},{"id":"M13251","name":"Phenylephrine","asFound":"Gut","relevance":"HIGH"},{"id":"M12721","name":"Oxymetazoline","asFound":"Gut","relevance":"HIGH"},{"id":"M7163","name":"Dopamine","asFound":"Audit","relevance":"HIGH"},{"id":"M17099","name":"Vasoconstrictor Agents","relevance":"LOW"},{"id":"M5262","name":"Cardiotonic Agents","relevance":"LOW"},{"id":"M11829","name":"Mydriatics","relevance":"LOW"},{"id":"M16035","name":"Sympathomimetics","relevance":"LOW"},{"id":"M17100","name":"Nasal Decongestants","relevance":"LOW"},{"id":"M20827","name":"Respiratory System Agents","relevance":"LOW"},{"id":"M20436","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M3358","name":"Adrenergic alpha-Agonists","relevance":"LOW"},{"id":"M3363","name":"Adrenergic Agonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M3719","name":"Central Nervous System Stimulants","relevance":"LOW"},{"id":"M17652","name":"Dopamine Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"VaCoAg","name":"Vasoconstrictor Agents"},{"abbrev":"CNSSti","name":"Central Nervous System Stimulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Resp","name":"Respiratory System Agents"},{"abbrev":"CaAg","name":"Cardiotonic Agents"}]}},"hasResults":false}